CEO and Managing Director
Dr Murdoch joined Phosphagenics as CEO in January 2015. He has more than 25 years experience as a leader within the global Healthcare, Pharmaceutical and Biotechnology Industry. He has held senior management and executive positions in Australia, USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses. Highlights of his career include Senior Vice President at Shire Pharmaceuticals (one of the world’s leading Specialty Pharmaceutical companies), based in the USA and Switzerland, where he founded and grew both the Emerging Products Business and Haematology Business, and President and COO of Prana Biotechnology Limited based in Australia. Dr Murdoch has a BSc degree with honours from Monash University, a PhD in Clinical Pharmacology from the University of Melbourne, and additional postgraduate training in Health Economics from Monash University Business School.
Dr Gavin is responsible for the global coordination and management of the company’s preclinical and clinical research. Since joining Phosphagenics in 2002, he has developed multiple opportunities for the Company such as transdermal drug delivery systems and drug enhancement platforms for chronic pain management. Dr Gavin is an inventor of the TPM® platform technology for transdermal delivery, and has managed its evolution from discovery to clinical development, with a range of products. Dr Gavin holds a BSc (Honours) and PhD in Biochemistry & Molecular Biology from Monash University, Melbourne. He is experienced in many aspects of R&D and has published a number of articles in peer reviewed journals.
GM Animal Health and Nutrition
Dr Libinaki is responsible for the global coordination and management of the company’s Animal Health and Nutrition, Research & Development programs. Since joining Phosphagenics in 2001, she has been involved and managed numerous, pre-clinical and clinical development programs with a focus on oral drug delivery systems and drug enhancement platforms to improve bioavailability and/or efficacy of a range of nutrients, and drug activities, for the purpose of improving health and well-being for both humans and animals. Dr Libinaki holds a Bachelor of Science (Biomedical) (Hons) and a PhD in Biochemistry and Molecular Biology from Monash University in Melbourne. She is also currently undertaking an Executive MBA with Monash University, Melbourne. She has collaborated and overseen numerous academic and commercial research programs and has extensively published in peer reviewed journals.